bevacizumab-irdye800cw
mAbexperimental
Clinical trial activity
10 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2018 (NCT03913806)
Timeline
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06008522 | N/A | Oct 1, 2023 | University of Groningen |
| NCT05262244 | Phase 1 | Jun 1, 2022 | University of Groningen |
| NCT06095362 | Phase 1 | Nov 29, 2021 | Dutch Cancer Society, University of Groningen |
| NCT05359874 | Phase 2 | Jun 30, 2021 | Technical University of Munich |
| NCT04212793 | Phase 1 | Mar 31, 2020 | University of Groningen |
| NCT03877601 | Phase 2 | Jul 31, 2019 | Helmholtz Centre for Infection Research, University of Groningen |
| NCT03925285 | Phase 1 | May 6, 2019 | University of Groningen |
| NCT03620292 | Phase 1/Phase 2 (Phase 2) | Aug 10, 2018 | University of Groningen |
| NCT03558724 | Phase 1 | Jul 2, 2018 | University of Groningen |
| NCT03913806 | Phase 1/Phase 2 (Phase 2) | May 1, 2018 | University of Groningen |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Groningen | Academic/Hospital | 9 | 9 | 3 | 2018 |
| Dutch Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Helmholtz Centre for Infection Research | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Technical University of Munich | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1